secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-273340
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

4DMT reports Q3 net loss $56.9M, enters Otsuka partnership for 4D-150 APAC rights for $85M upfront
--------------------------------------------------------------------------------

- Net loss $56.9M in Q3 2025 vs $43.8M in Q3 2024; R&D expenses $49.4M (up from $38.5M).
- Otsuka partnership: $85M upfront + $50M cost sharing; up to $336M milestones + royalties. 4DMT retains ex-APAC rights.
- Cash $372M at Sept 30; + Otsuka payments + $93M equity raise extends runway into H2 2028.
- 4FRONT Phase 3 enrollment: >200 patients randomized in 4FRONT-1; topline data H1 2027. 4FRONT-2 on track.
- Positive long-term PRISM (wet AMD) and SPECTRA (DME) data; 4D-150 well tolerated with durable benefit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000119312525273340/0001193125-25-273340-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000119312525273340/fdmt-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-273340

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer